$CMND

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Clearmind Medicine Inc. (Nasdaq: CMND) reported early Phase I/IIa first-in-human trial updates for CMND-100, its non-hallucinogenic MEAI compound for alcohol use disorder, based on a June 10 webinar. Investigators from Yale and Johns Hopkins cited generally positive impressions, good volunteer recruitment, and an early safety profile with no meaningful adverse or cardiac concerns to date.

Clearmind Medicine (Nasdaq: CMND) said it submitted a formal response to a U.S. HHS Request for Information on MEAI as an innovative addiction treatment under the Great American Recovery Initiative. The company highlighted its MEAI-based candidate CMND-100 for alcohol use disorder, citing AUD prevalence of about 10% of the U.S. population and low abuse potential.

Clearmind Medicine Inc. (Nasdaq: CMND) said it submitted a formal response to a U.S. HHS Request for Information on MEAI for addiction treatment under the Great American Recovery Initiative. The company highlighted its MEAI-based candidate CMND-100 for alcohol use disorder, citing AUD affects about 10% of the U.S. population and only 1 in 10 receives treatment.

HRT FINANCIAL LP purchased 2,159,052 shares of Clearmind Medicine Inc. (CMND) at $0.15 ($0.33M total) on 2026-06-10.

Clearmind Medicine Inc. (CMND) shares rose 46.72% to $3.59 on Friday after the company said a Japanese patent application was published for its depression treatment. The filing covers compositions using 5-Methoxy-2-aminoindan (MEAI), strengthening its intellectual property portfolio. Volume was 41.05 million shares versus 612,955 average.

Clearmind Medicine Inc. (CMND) shares rose 46.72% to $3.59 on Friday after the company said a Japanese patent application was published covering compositions using 5-Methoxy-2-aminoindan (MEAI) for depression treatment. The filing, the company said, adds to its intellectual property portfolio for non-hallucinogenic neuroplastogen-derived therapeutics. Volume was 41.05 million shares versus 612,955 average.

MarketBeat compared Relmada Therapeutics (NASDAQ:RLMD) and Clearmind Medicine (NASDAQ:CMND). RLMD has a consensus target price of $12.00 (67.95% upside) versus CMND’s lower outlook, and RLMD is trading at a lower P/E. Institutional ownership is 45.2% for RLMD and 96.1% for CMND; beta is 0.43 for RLMD and 0.87 for CMND.

Clearmind Medicine Inc. (NASDAQ: CMND) has filed a Form F-3 to register for resale up to 22,626,988 common shares. These shares are tied to the conversion of up to $10.0M in principal plus accrued interest from convertible promissory notes held by institutional investors, assuming a conversion price of $0.60 per share, which represents approximately 222% of pre-offering outstanding shares. The company will not receive any proceeds from the resale of these registered shares, as all net proceeds will go to the selling shareholders, but it has already received $8.15M in gross proceeds from the promissory notes.

Clearmind Medicine's CMND-100, a non-hallucinogenic psychedelic treatment for Alcohol Use Disorder (AUD), has successfully met its primary safety endpoint in its FDA-approved Phase I/IIa trial. This marks a significant step forward for the therapy, with 18 participants completing treatment and no major safety issues reported by the Data Safety Monitoring Board. While the stock reaction was mixed, this safety milestone positions CMND-100 for potential efficacy studies and offers a promising new option for AUD patients and investors in the psychedelic medicine sector.